Pacylex News has migrated to Newsroom. Click the link below to access the latest articles and press releases.
Pacylex today announced that the US Department of Defense (DOD) awarded The University of Texas MD Anderson Cancer Center $1.4 million to treat Acute Myeloid Leukemia (AML) patients with PCLX-001, a first-in-class N-myristoylation inhibitor in clinical development by Pacylex.